2020 Revenues ($USD) : $13,444,600,000
2020 R&D spend : $3,990,900,000
2020 Number of Employees : 9,100
Fiscal Year End : 12/31/2020
Key People : Michel Vounatsos, CEO; Susan Alexander, chief legal officer and secretary; Alphonse Galdes, head of pharmaceutical operations and technology and technology; Ginger Gregory, chief human resources officer; Chirfi Guindo, head of global product strategy and commercialization; Michael McDonnell, CFO  

Biogen is developing therapeutics for people living with serious neurological and neurodegenerative diseases and related therapeutic adjacencies. The Cambridge, Mass.-based company makes medicines to treat multiple sclerosis and spinal muscular atrophy. It is also focused on advancing research programs with neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain. Biogen commercializes 15 drugs globally, with Tecfidera and Vumerity leading its product sales. –DK